BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260701T093000
DTEND;TZID=Europe/Brussels:20260701T133000
DTSTAMP:20260728T014111
CREATED:20260505T073147Z
LAST-MODIFIED:20260519T114509Z
UID:9589-1782898200-1782912600@www.europabio.org
SUMMARY:EuropaBio Biomanufacturing Policy Summit 2026
DESCRIPTION:From legislation to impact for Europe \n\n\n\nBiomanufacturing lies at the heart of Europe’s future societal and entrepreneurial strength and is changing the business landscape for both emerging innovators and established industry champions. \n\n\n\nEuropaBio’s 4th Biomanufacturing Policy Summit will focus on how legislation delivers impact within a proactive Biomanufacturing strategy\, and how we establish EU targets for outcomes. It will also showcase the 2026 update of the EuropaBio WIfoR study ‘Measuring the Economic Footprint of the Biotechnology Industry in the European Union’ prior to full report launch in September. \n\n\n\nThe prize is globally competitive multi-sector biomanufacturing\, keeping pace with industrial transition in major global regions and securing Europe’s supply chains\, healthcare future\, decarbonisation and economic resilience. \n\n\n\nThis meeting will bring together EuropaBio Members\, representatives of key sectors\, plus national and EU stakeholders across institutions. \n\n\n\nThis event will be accessible by invitation only\, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org
URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2026/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/05/Event-Banner-EuropaBio-Biomanufacturing-Policy-Summit-2026.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260611T090000
DTEND;TZID=Europe/Brussels:20260611T133000
DTSTAMP:20260728T014111
CREATED:20260424T102431Z
LAST-MODIFIED:20260424T102433Z
UID:9607-1781168400-1781184600@www.europabio.org
SUMMARY:European Biotech Forum 2026
DESCRIPTION:EuropaBio is a proud sponsor of the European Biotech Forum 2026. \n\n\n\nBiotechnology is becoming a decisive capability for Europe’s competitiveness\, industrial resilience and strategic autonomy. But Europe enters the next institutional cycle with a fragmented policy landscape\, uneven regulatory capacity\, and persistent scale-up barriers. The Commission’s Biotech Communication I and Biotech Communication II set out an initial toolbox\, but fall short of an end-to-end industrial framework comparable to the US. The gap between ambition and execution remains significant. To what extent do these communications address the core challenges of Europe’s biotech sector? Where are the structural gaps that still block growth and industrial deployment? \n\n\n\n\nMore Info & Registration Here
URL:https://www.europabio.org/event/european-biotech-forum-2026/
CATEGORIES:EuropaBio,External,Healthcare Biotech,Industrial Biotech,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/04/Event-Banners-Website-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260603T080000
DTEND;TZID=Europe/Brussels:20260604T200000
DTSTAMP:20260728T014111
CREATED:20260113T081624Z
LAST-MODIFIED:20260113T081823Z
UID:9392-1780473600-1780603200@www.europabio.org
SUMMARY:ECRD 2026: Rare Diseases in a changing & Competitive Europe
DESCRIPTION:ECRD is the largest\, patient-led policy-shaping conference for rare diseases in Europe. The event is an instrumental tool for advancing policy objectives that improve the lives of people living with a rare disease. The overarching title of ECRD 2026 is: Rare Diseases in a Changing & Competitive Europe: Shaping policies to address the unmet needs of people living with rare diseases.  \n\n\n\nRare disease research has long driven breakthroughs in more common conditions\, reinforcing Europe’s role as a global leader in biotechnology and precision medicine. Investing in this field is not only a moral imperative—it is a strategic move to boost Europe’s competitiveness in the life sciences. This is especially crucial in the context of the deployment of the Life Science Strategy and of the adoption of the Biotech Act.  \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/ecrd-2026-rare-diseases-in-a-changing-competitive-europe/
CATEGORIES:External,Healthcare Biotech,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/01/Event-Banners-Website-32.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260519T080000
DTEND;TZID=Europe/Brussels:20260521T200000
DTSTAMP:20260728T014111
CREATED:20260312T090221Z
LAST-MODIFIED:20260312T090324Z
UID:9518-1779177600-1779393600@www.europabio.org
SUMMARY:EU Pharmaceutical Law Forum 2026
DESCRIPTION:We are thrilled to announce our partnership with the EU Pharmaceutical Law Forum\, one of the most significant events for legal and compliance professionals in the pharmaceutical industry.This forum is a cornerstone for discussing the latest developments in EU pharmaceutical law\, regulatory frameworks\, and compliance strategies. It brings together industry leaders\, legal experts\, and policymakers to address critical challenges and opportunities\, shaping the future of healthcare and pharmaceuticals in Europe.As part of our partnership\, we are delighted to offer 15% off registration* to our audience! Don’t miss this opportunity to gain valuable insights\, network with key stakeholders\, and stay ahead in the ever-evolving pharmaceutical landscape. \n\n\n\n*This discount is applicable to Life Sciences Manufacturers only. Other restrictions may apply. \n\n\n\nDiscount code: EUPLEUBIO26 \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/eu-pharmaceutical-law-forum-2026/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/03/Event-Banners-Website-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260512T080000
DTEND;TZID=Europe/Brussels:20260513T200000
DTSTAMP:20260728T014111
CREATED:20260424T101919Z
LAST-MODIFIED:20260424T101921Z
UID:9605-1778572800-1778702400@www.europabio.org
SUMMARY:EFGCP Conference 2026
DESCRIPTION:EuropaBio is supporting EFGCP Conference 2026. \n\n\n\nEurope is at a defining moment for clinical research. The Clinical Trials Regulation set out a powerful vision: a continent united by transparency\, collaboration\, and efficient access to innovation. While its implementation brought both progress and pressure\, it confirmed something essential—Europe’s commitment to ethics\, quality\, and patient protection remains unwavering. \n\n\n\nNational ethical review is a vital strength of Europe’s clinical research landscape. Ethics committees play a key role in ensuring trials uphold human dignity\, scientific integrity\, and public trust. Their contribution\, together with the regulatory authorities’ risk-benefit review\, forms the foundation of a credible and high‑quality research ecosystem. By further strengthening the collaborative partnership\, Europe can achieve an ethical review process that is both protective and efficiently aligned with the needs of modern clinical research. \n\n\n\nToday\, national ethical review stands at the centre of the conference discussion. Ethics committees face growing complexity; sponsors navigate longer reviews and more information requests. These challenges highlight not failure\, but opportunity: the chance to rethink how Europe aligns ethical excellence with operational efficiency. \n\n\n\nIn addition\, the European Commission’s proposed new Biotech Act offers a fresh pathway—clearer roles\, streamlined processes\, and modern ethical standards grounded in the 2024 Declaration of Helsinki. It invites us to shape a system worthy of Europe’s innovation leadership ambitions. \n\n\n\nThe EFGCP Conference 2026 is where this work begins. Here\, stakeholders from across Europe come together to share best practice experiences\, challenge assumptions\, and co‑create practical solutions to optimise the system. Our goal is simple and ambitious: to strengthen participant protection while enabling efficient\, faster\, more predictable clinical trial authorisations and start up times. \n\n\n\nTogether\, we have the opportunity to build an ethical review model that reflects Europe at its best—responsible\, collaborative\, transparent and ready to lead the next chapter of global research. \n\n\n\n\nMore Info & Registration Here
URL:https://www.europabio.org/event/efgcp-conference-2026/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/04/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260506T080000
DTEND;TZID=Europe/Brussels:20260506T200000
DTSTAMP:20260728T014111
CREATED:20260219T124023Z
LAST-MODIFIED:20260219T124028Z
UID:9479-1778054400-1778097600@www.europabio.org
SUMMARY:BioPharmaChem Impact 2026
DESCRIPTION:BioPharmaChem 2026 will bring together leading business leaders and experts on many pertinent topics including: realising the potential of the ecosystem\, sustainability\, digitalisation\, the power of partnerships\, resilient supply chains\, the future of work\, EU competitiveness and more. \n\n\n\nDelegates will enjoy unmissable networking opportunities to connect with many biopharmaceuticals\, pharmaceuticals and chemicals professionals in our bespoke exhibition area. \n\n\n\nThe Awards Dinner will honour excellence in the BioPharmaChem sector and celebrate the remarkable contributions and innovations that are shaping the future of our industry. This will provide a fitting end to a truly engaging event. \n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/biopharmachem-impact-2026/
CATEGORIES:External,Healthcare Biotech,Industrial Biotech,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-41.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260429T080000
DTEND;TZID=Europe/Brussels:20260429T200000
DTSTAMP:20260728T014112
CREATED:20260219T123316Z
LAST-MODIFIED:20260219T123318Z
UID:9476-1777449600-1777492800@www.europabio.org
SUMMARY:Made by Cells - Biotech Forum
DESCRIPTION:Join our Director General Dr Claire Skentelbery in Finland! \n\n\n\nJoin us at the Hanaholmen Cultural Center in Espoo Finland for inspiring talks on Pharma & Diagnostics\, Food\, Pigments and Polymers\, alongside valuable networking opportunities with leading biotech innovators and stakeholders. Discover cutting-edge advancements and collaborate to shape the future of biotechnology. The event is organised in collaboration with VTT Technical Research Center of Finland \n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/made-by-cells-biotech-forum/
CATEGORIES:External,Healthcare Biotech,Industrial Biotech,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-40.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260422T080000
DTEND;TZID=Europe/Brussels:20260423T200000
DTSTAMP:20260728T014112
CREATED:20260304T091600Z
LAST-MODIFIED:20260304T091605Z
UID:9498-1776844800-1776974400@www.europabio.org
SUMMARY:CEBioForum 2026
DESCRIPTION:CEBioForum 2026 is a leading international biotechnology conference bringing together professionals from Central and Eastern Europe and beyond. With over 20 years of tradition\, CEBioForum serves as a trusted platform for dialogue\, partnership-building\, and knowledge exchange across the life sciences ecosystem. \n\n\n\nThe two-day event will take place in the modern spaces of CIC Warsaw\, located in the very center of the city\, and will feature a comprehensive program including high-level panel discussions\, keynote presentations\, startup pitch sessions\, an exhibition area\, and structured B2B networking supported by a dedicated event app. An evening networking reception and the CEBioForum Awards ceremony will further strengthen opportunities for meaningful connections. \n\n\n\nThe conference agenda will focus on the most relevant trends and challenges shaping the future of biotechnology and life sciences\, including biotech and pharma innovation\, medtech\, clinical trials\, data and AI in healthcare\, venture capital and financing in CEE\, cross-border collaboration\, dual-use technologies\, and pathways for scaling European innovations to global markets\, particularly the US. \n\n\n\nCEBioForum 2026 is the place to discover the dynamic Polish and CEE biotech ecosystem\, meet decision-makers\, investors\, entrepreneurs\, and researchers\, and explore opportunities for collaboration\, investment\, and growth in one of Europe’s fastest-developing life science regions. \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/cebioforum-2026/
CATEGORIES:External,Healthcare Biotech,Industrial Biotech,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/03/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260414T143000
DTEND;TZID=Europe/Brussels:20260414T153000
DTSTAMP:20260728T014112
CREATED:20260309T135321Z
LAST-MODIFIED:20260309T143349Z
UID:9503-1776177000-1776180600@www.europabio.org
SUMMARY:The EU Biotech Act: Europe’s ambition for biotechnology
DESCRIPTION:Join Director General Sandra Gallina and EuropaBio to explore the EU Biotech Act proposal\, published in December 2025. \n\n\n\nThe webinar explores the Goal of the Act\, to boost innovation\, support development of biotech products and accelerate time-to-market\, making use of industrial enablers and regulatory simplification. \n\n\n\nThis webinar will introduce the drivers behind the Biotech Act proposal plus its diverse and ambitious mechanisms to boost EU biotech delivery. It will discuss how mechanisms might work and the interlink of the Act with the wider European Legislative landscape\, and its legislative pathway into action for the EU. \n\n\n\nWebinar delegates will have the opportunity to ask Director General Gallina questions during the event and EuropaBio will publish a summary for all participants. \n\n\n\nAGENDA \n\n\n\n\n\n\n\n\n14h30: Introduction – Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n\n\n\n\n\n\n14h40: The Biotech Act in focus – Director General Sandra Gallina\, DG Health and Food Safety\, European Commission: \n\n\n\n\n\nRegulatory streamlining and facilitation in health\, food and other biotech\n\n\n\nIndustrial enablers including High Impact Strategic Projects\, Boosting innovative biotech & biosimilars\, Access to Finance\, AI and Data\, Biosecurity & Defence\n\n\n\n\n15h10: Discussion and audience Q&A \n\n\n\n15h30: Close \n\n\n\nWho should attend? If you are active within biotechnology in any sector\, you should attend to understand what the Act means for you\, how you should be involved and what happens next. \n\n\n\nRegister below \n\n\n\n\nRegistration Here
URL:https://www.europabio.org/event/the-eu-biotech-act-europes-ambition-for-biotechnology/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/03/Event-Banners-Website-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T163000
DTEND;TZID=Europe/Brussels:20260323T180000
DTSTAMP:20260728T014112
CREATED:20260317T081056Z
LAST-MODIFIED:20260317T081058Z
UID:9523-1774283400-1774288800@www.europabio.org
SUMMARY:Special feature: Biotech Act Part I – Dr Claire Skentelbery\, Director General EuropaBio @ BIO-Europe Spring 2026
DESCRIPTION:Join our Director General Dr Claire Skentelbery at BIO-Europe Spring on the 23rd of March for an afternoon session dedicated to the EU Biotech Act Part 1. \n\n\n\nThe EU Biotech Act represents a landmark piece of legislation aimed at positioning Europe as a global leader in biotech. Structured in two parts\, the legislative program seeks to drive competitiveness across multiple sectors. Part I of the EU Biotech Act\, published in December 2025\, focuses on advancing health innovation. Key initiatives include accelerating clinical trials\, extending intellectual property protections\, launching a robust investment program\, and introducing strategic projects designed to achieve critical mass in applied innovation. Part II\, set to be unveiled in 2026\, will shift the focus toward maximising biomanufacturing across industries\, further strengthening Europe’s biotech ecosystem. \n\n\n\nThis feature session is dedicated to the Biotech Act part\, including a Keynote and Fireside Chat. \n\n\n\n16:30 Keynote presentation: Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n17:00 Fireside chat: Dr Claire Skentelbery in discussion with Dr Tilo Mandry\, Lead International Liaison Manager IGES \n\n\n\n17:15: Session: Special feature: Biotech Act Part I – What’s in it for me? Industry panel discussionPanelists:– Dr Morgane Rousselot\, Founder\, Chairwoman and CEO\, SeaBeLife Biotech– Dr Ann Belien\, Founder & CEO\, Rejuvenate Biomed (tbc)– Andreas Prenner\, Policy Officer\, European Commission– Dr Marjo Puumalainen\, International Director\, SwedenBIO– Dr Tilo Mandry\, Lead International Liaison Manager\, IGES (Moderator) \n\n\n\nThis panel continues the EU Biotech Act Special Feature: We will discuss what the Biotech Act means for biotech companies and Europe as a biotech investment location\, and how companies can best adapt to its provisions. \n\n\n\nThere are many questions about the Biotech Act:– How will industrial clinical research be accelerated and how will this affect the development of innovative therapies?– How will the Biotech Act impact the financing of innovative biotech start-ups?– Can cell and gene therapies now be developed more quickly by companies in the EU and brought to patients more easily?– What does the extension of intellectual property protection mean for biopharmaceutical companies in practice?– Is the Act sufficiently targeted at industry and where are the risk points?– And finally\, can the EU compete globally\, particularly with the US and China\, thanks to the Biotech Act?We will discuss these and many other important aspects with the panelists and the audience. \n\n\n\n18:00: Close \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/special-feature-biotech-act-part-i-dr-claire-skentelbery-director-general-europabio-bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,EuropaBio,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T080000
DTEND;TZID=Europe/Brussels:20260325T200000
DTSTAMP:20260728T014112
CREATED:20260219T090517Z
LAST-MODIFIED:20260219T090524Z
UID:9470-1774252800-1774468800@www.europabio.org
SUMMARY:BIO-Europe Spring 2026
DESCRIPTION:EuropaBio is joining BIO-Europe Spring 2026. \n\n\n\nBIO-Europe Spring is Europe’s largest springtime biotech partnering event\, bringing together over 3\,700 leaders and innovators in the life sciences industry. It’s designed for partnering\, business development\, and licensing opportunities in biotechnology and pharmaceuticals. \n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260201T080000
DTEND;TZID=Europe/Brussels:20260203T200000
DTSTAMP:20260728T014112
CREATED:20260115T140153Z
LAST-MODIFIED:20260115T140155Z
UID:9411-1769932800-1770148800@www.europabio.org
SUMMARY:EUCROF26
DESCRIPTION:Building on the momentum of nearly 350 attendees at EUCROF25\, EUCROF26 will once again bring together clinical research professionals from across Europe and beyond. Expect three days of high-impact networking\, thought-provoking sessions\, and future-focused dialogue designed to accelerate innovation and excellence in our field. \n\n\n\nJoin our Director General Claire Skentelbery from 1–3 February 2026 as we shape the next chapter of clinical research; together. \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/eucrof26/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/01/Event-Banners-Website-34.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20251104T080000
DTEND;TZID=Europe/Brussels:20251105T200000
DTSTAMP:20260728T014112
CREATED:20250923T113512Z
LAST-MODIFIED:20250923T113512Z
UID:9227-1762243200-1762372800@www.europabio.org
SUMMARY:IHI Brokerage Event 2025
DESCRIPTION:Registration is now open for the IHI Brokerage Event 2025\, which will be held in Brussels\, Belgium on 4-5 November. The event is a prime opportunity for potential applicants to network and start forming consortia for IHI’s next single-stage call for proposals\, which is scheduled for launch in early 2026. \n\n\n\nRegistration is free but obligatory via the event and networking platform. Note that if you signed up to last year’s brokerage platform\, you will receive an e-mail with instructions on how to transfer your profile to the new platform. \n\n\n\nThe brokerage event has been designed to facilitate networking and the formation of consortia for IHI’s next calls for proposals. Find out about the different features of the event… \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/ihi-brokerage-event-2025/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/09/Event-Banners-Website-31.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20251027T080000
DTEND;TZID=Europe/Brussels:20251029T200000
DTSTAMP:20260728T014112
CREATED:20250326T110753Z
LAST-MODIFIED:20250326T110753Z
UID:8933-1761552000-1761768000@www.europabio.org
SUMMARY:World Orphan Drug Congress 2025
DESCRIPTION:The World Orphan Drug Congress Europe is the largest and most established event globally for orphan drugs and rare diseases. \n\n\n\nJoin over 2\,000 attendees\, gain insights from 250+ industry leaders\, and connect with over 130 exhibitors as we bring together experts across the entire orphan drug lifecycle\, discussing areas including regulatory affairs and policy to global pricing and cutting-edge gene therapies. \n\n\n\nThe attendees represent the most senior individuals across the industry\, including leaders in R&D\, gene therapy\, rare diseases\, precision/personalised medicine\, genetic disorders\, patient advocacy and engagement\, associations in ATMPs\, investors\, regulatory affairs professions\, governmental bodies\, and more… \n\n\n\nFind out more and get your tickets using the link below. Get 20% off with the code: EUBIO20 \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/world-orphan-drug-congress-2025/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/03/Event-Banners-Website-7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20251015T120000
DTEND;TZID=Europe/Brussels:20251015T210000
DTSTAMP:20260728T014112
CREATED:20250505T110759Z
LAST-MODIFIED:20250814T132321Z
UID:9042-1760529600-1760562000@www.europabio.org
SUMMARY:Biotech & Biomanufacturing Policy Summit
DESCRIPTION:EuropaBio is pleased to host its third Summit focused on biotechnology & biomanufacturing. \n\n\n\nBiotechnology is a critical technology for Europe.  Delivery of innovation into market drives competitiveness\, security\, supply chain resilience plus societal and environmental goals.  Europe must be ambitious and globally aware\, with a focus on securing its biotechnology capability within fast changing global geopolitics. \n\n\n\nThe current Commission has a significant opportunity to set and deliver on the ambition needed. Legislation such as the Biotech Act\, plus the frameworks that we create for sectors including health\, agri-food and manufacturing. \n\n\n\nThe half day Summit brings together EuropaBio Members and stakeholders to understand the ambition needed for legislation\, how the EU and its Member States can deliver and recognition of global positioning needed. \n\n\n\nIt is supported by biotech product displays and EU projects\, plus evening networking reception. It will be followed by a Summit Statement and public webinar hosted in November. \n\n\n\nAgenda: \n\n\n\n12:30 Registration and lunch13:15 Welcome and Keynote session Summit keynotes bring Industry\, Parliament and Commission perspectives to Europe’s ambition for biotech and biomanufacturing and the policy framework currently in action. Commissioner Olivér Várhelyi – Commissioner for Health and Animal Welfare Markus Staempfli – EuropaBio Chair\, Vice President Europe Major Markets & Canada\, CSL Behring MEP Stine Bosse – MEP and co-chair EU Alliance of Biotech and Life Sciences14:00 Panel sessions The current legislative cluster impacting biotechnology and biomanufacturing is in focus for our panel discussions. Stakeholders from across industry\, policy and member states discuss what Europe’s ambition must be and how individual and aligned legislations can deliver.Panel 1 – Enabling EU markets How policy creates markets for biotech products and enables biomanufacturing processes.Panel 2 – Enhancing access How market pathways are vital for product and process commercial viability\, determining speed and scale of access and uptake.Panel 3 – Building the EU ecosystem How knowledge\, skills\, finance and infrastructure deliver on market potential for Europe.17:50 Pre-reception remarks18:00 Reception20:30 Close\n\n\n\nThis event will be accessible by invitation only\, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org
URL:https://www.europabio.org/event/biotech-biomanufacturing-policy-summit/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/05/Event-Banner-Website-Biotech-Biomanufacturing-Policy-Summit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250917T080000
DTEND;TZID=Europe/Brussels:20250918T200000
DTSTAMP:20260728T014112
CREATED:20250618T121730Z
LAST-MODIFIED:20250618T121731Z
UID:9127-1758096000-1758225600@www.europabio.org
SUMMARY:Life Sciences Baltics 2025
DESCRIPTION:Join our Director General Claire Skentelbery at the Life Sciences Baltics 2025 conference where she will be speaking on The EU Biotech Act – leading Europe’s evolution and revolution for competitiveness. \n\n\n\nLife Sciences Baltics is the leading event in the Baltic region\, connecting global life sciences professionals. This event provides unique opportunities for project initiation\, lead generation\, and strategic partnerships through an extensive exhibitor showcase\, insightful conferences\, a dedicated partnering area\, diverse networking formats\, and competitions\, including a startup pitch challenge. \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/life-sciences-baltics-2025/
CATEGORIES:External,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/06/Event-Banners-Website-27.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250916T080000
DTEND;TZID=Europe/Brussels:20250917T200000
DTSTAMP:20260728T014112
CREATED:20250618T114107Z
LAST-MODIFIED:20250618T114107Z
UID:9115-1758009600-1758139200@www.europabio.org
SUMMARY:Nordic Rare Disease Summit 2025
DESCRIPTION:The scene has already been set\, the roadmap for change is in our hands. \n\n\n\nTaking place at the heart of Copenhagen on 16 & 17 September\, alongside the Danish Presidency of the European Union\, the 2025 Nordic Rare Disease Summit will gather the leading experts within academia and healthcare professionals\, patients\, decision-makers and industry to discuss solutions; with the joint aspiration of improving the quality of life for people living with rare diseases. \n\n\n\nBuilding on prior summits in 2021 and 2023\, the 2025 summit ‘pushing boundaries for rare’ will centre patient empowerment as a key theme. \n\n\n\nThe expertise of people living with a rare disease must be acknowledged as a resource from the level of individual patients to that of the community\, and as a foundation for policymaking in the Nordics and the European Union. Together we can do more. \n\n\n\n \n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/nordic-rare-disease-summit-2025/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/06/Event-Banners-Website-24.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250902T080000
DTEND;TZID=Europe/Brussels:20250904T200000
DTSTAMP:20260728T014112
CREATED:20250618T115945Z
LAST-MODIFIED:20250618T120020Z
UID:9118-1756800000-1757016000@www.europabio.org
SUMMARY:Advanced Therapies Europe 2025
DESCRIPTION:Now in its 5th year\, Advanced Therapies Europe 2025 is an intentionally intimate event — limited to just 500 senior-level decision-makers — to ensure every conversation drives outcomes. Held in Barcelona\, at the heart of Europe’s fast-growing biotech ecosystem\, this is where strategic connections ignite progress and insights lead to action. Whether you’re here to invest\, scale\, partner\, or launch\, ATE 2025 gives you the platform to make it happen. \n\n\n\n \n\n\n\nEuropaBio Director General Dr Claire Skentelbery will take the stage in our Opening Plenary to explore the state of the CGT industry and what Europe must do now to secure its global leadership. With U.S. support for scientific innovation under pressure\, the time is now for Europe to sharpen its edge in scalability\, affordability\, and patient access. \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/advanced-therapies-europe-2025/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/06/Event-Banners-Website-25.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250701T150000
DTEND;TZID=Europe/Brussels:20250701T170000
DTSTAMP:20260728T014112
CREATED:20250618T120817Z
LAST-MODIFIED:20250618T120910Z
UID:9122-1751382000-1751389200@www.europabio.org
SUMMARY:Nordic Rare Disease Roadmap Launch at the European Parliament
DESCRIPTION:Join us at the European Parliament on Tuesday 1 July\, from 15:00 to 17:00. Members of the European Parliament Stine Bosse (Renew Europe\, Denmark) and Maria Guzenina (Socialists and Democrats\, Finland) are hosting the event\, which coincides with Denmark assuming the Presidency of the Council of the European Union. This European Parliament event will bring together key stakeholders to mark an important step forward in our shared work to drive action for the more than 1 million people living with rare diseases in the Nordics and more than 30 million people living with rare diseases in Europe!  \n\n\n\nOur Director General Dr Claire Skentelbery will be speaking on the panel Rare diseases in the EU agenda: A call for a collective response. \n\n\n\nThis event is supported by the Nordic Rare Disease group – namely EURORDIS\, SBONN\, Sjældne Diagnoser\, Novo Nordisk\, Takeda\, Alexion\, Sobi\, UCB\, EFPIA\, EuropaBio\, and EUCOPE. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/nordic-rare-disease-roadmap-launch-at-the-european-parliament/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/06/Event-Banners-Website-26.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250513T160000
DTEND;TZID=Europe/Brussels:20250513T180000
DTSTAMP:20260728T014112
CREATED:20250422T074400Z
LAST-MODIFIED:20250430T072534Z
UID:9000-1747152000-1747159200@www.europabio.org
SUMMARY:Patient BioForum 2025
DESCRIPTION:The theme of the Patient BioForum 2025 is From discovery to access: towards a patient-centric health European ecosystem. \n\n\n\nThe event is hosted by MEP András Tivadar Kulja\, who will hold a keynote speech\, and concluding remarks will be given by MEP Stine Bosse. \n\n\n\nThe panel discussion is moderated by Dr. Nicholas Whyte (Senior Director – APCO) and includes: \n\n\n\nRosa Castro (Public Affairs Director\, EURORDIS)\,  \n\n\n\nLeire Solis\, (Health Policy and Advocacy Director\, IPOPI)\,  \n\n\n\nSolène Jouan (Policy Officer\, European Patients’ Forum)\, \n\n\n\nIrene de Cara Torres (Head of Policy and Government Affairs International\, CSL Behring)\, \n\n\n\nDr. Claire Skentelbery (Director General\, EuropaBio)\, \n\n\n\nRainer Becker (Director SANTE.D Medical Products and Innovation). \n\n\n\n \n\n\n\nThe event gathers patients organisations\, industry leaders and representatives of EU institutions to discuss how the regulatory framework and future legislations (General Pharmaceutical Legislation\, EU Biotech Act and Critical Medicines Act) will support innovation\, availability\, and access to medicines for EU patients. \n\n\n\nEuropaBio’s Patient BioForum aims to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations\, the biopharmaceutical industry and policy makers. \n\n\n\nFor more information\, please contact Beatrice Rocco: b.rocco@europabio.org \n\n\n\nRegistrations for people that do not have a badge to access the European Parliament will close at 12:00 on 6 May 2025. People that have a badge can register beyond this date.  \n\n\n\n \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/patient-bioforum-2025/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2025/04/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250507T000000
DTEND;TZID=Europe/Brussels:20250508T235959
DTSTAMP:20260728T014112
CREATED:20250303T145152Z
LAST-MODIFIED:20250303T145236Z
UID:8834-1746576000-1746748799@www.europabio.org
SUMMARY:Knowledge for Growth 2025
DESCRIPTION:Mark your calendar for Knowledge for Growth 2025\, Europe’s premier life sciences conference\, taking place on 8 May 2025 in the dynamic city of Antwerp\, Belgium! \n\n\n\nConnect with over 1\,000 life sciences professionals from 500+ companies and organisations\, including decision-makers from biotech\, pharma\, MedTech\, AgTech\, and healthtech\, as well as investors\, universities\, research institutes\, policymakers\, and service providers. \n\n\n\nImmerse yourself in an action-packed programme offering exclusive insights into the global and regional life sciences landscape\, one-to-one partnering\, a vibrant trade fair\, and countless networking opportunities. \n\n\n\nDon’t miss the chance to elevate your knowledge and expand your network at Knowledge for Growth 2025! \n\n\n\nUSE CODE: KFG2025CLUSTER15 FOR A 15% DISCOUNT \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/knowledge-for-growth-2025/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/03/Event-Banners-Website-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250403T133000
DTEND;TZID=Europe/Brussels:20250403T150000
DTSTAMP:20260728T014112
CREATED:20250224T145353Z
LAST-MODIFIED:20250224T145353Z
UID:8810-1743687000-1743692400@www.europabio.org
SUMMARY:Unlocking efficiency through reliance: Navigating the EMA post-authorization framework
DESCRIPTION:This joint webinar\, organised in partnership between the EMA and the industry\, aims to provide a platform for discussion and awareness on current and future EMA post-authorization framework\, including variations and renewals. This event builds up on last year’s session: “Regulatory Reliance Tools Unveiled – A Practical Guide by EMA.” \n\n\n\nThis year\, we will further explore how EMA assessment outputs can support regulatory reliance pathways\, helping to streamline the approval of variations (CMC\, clinical/safety) efficiently and sustainably. \n\n\n\nSpearheaded by EMA\, with the participation of WHO and global regulators\, the webinar will: \n\n\n\n\nExplain EMA’s variations and renewals process.\n\n\n\nDescribe the purpose and content of assessment document outputs and their relevance for regulatory reliance.\n\n\n\nAddress participant questions to enhance understanding and application of these tools.\n\n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/unlocking-efficiency-through-reliance-navigating-the-ema-post-authorization-framework/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/02/Event-Banners-Website-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250129T183000
DTEND;TZID=Europe/Brussels:20250129T203000
DTSTAMP:20260728T014112
CREATED:20241217T125548Z
LAST-MODIFIED:20250128T102313Z
UID:8543-1738175400-1738182600@www.europabio.org
SUMMARY:A Driver of European Competitiveness: The Future of European Biotech
DESCRIPTION:EuropaBio\, the European association representing Bioindustries\, will host an evening reception co-hosted by MEP Stine Bosse (Vice-Chair\, SANT) and MEP Eszter Lakos (Member\, ITRE)\, to discuss the role of the European biotech sector in making the European industry more competitive. \n\n\n\nAmbassador Søren Jacobsen\, Deputy Permanent Representative of Denmark to the EU\, and Kristin Schreiber\, Director at DG GROW\, Klaus Berend\, Director SANTE will share some remarks on their approach to the biotech sector in the new mandate. \n\n\n\nThis event is only open to EuropaBio members & invited guests\, to find out more about EuropaBio membership\, contact us through our website here.
URL:https://www.europabio.org/event/a-driver-of-european-competitiveness-the-future-of-european-biotech/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/12/EUROPABIO.6788f179502696.54888785.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250128T140000
DTEND;TZID=Europe/Brussels:20250128T180000
DTSTAMP:20260728T014112
CREATED:20241126T083629Z
LAST-MODIFIED:20241126T083631Z
UID:8485-1738072800-1738087200@www.europabio.org
SUMMARY:EU Health Summit
DESCRIPTION:Healthy populations are essential for Europe to achieve its vision of a secure\, competitive\, and prosperous continent. Yet\, European health systems are navigating a perfect storm: ageing populations\, rising chronic diseases\, and a health workforce under strain. European societies are facing combined cost-of-living\, geopolitical\, and climate crises with significant implications for healthcare. \n\n\n\nAmid these challenges\, we must not lose sight of the extraordinary era we are living in—one of rapidly advancing science and innovation\, transforming health and unlocking new possibilities for Europe’s present and future generations. \n\n\n\nKeeping the health sector high on the political agenda is essential for the well-being of Europeans\, a resilient workforce\, the growth of the EU economy\, and the security of Europe. This is why\, during this EU mandate\, we need a robust and integrated strategy for health policy. \n\n\n\nWhat needs to be done in practice? \n\n\n\nJoin the EU Health Summit on 28 January to help shape a roadmap for a healthier Europe. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/eu-health-summit/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/11/External-Events-Banners-600-×-200px-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241022T080000
DTEND;TZID=Europe/Brussels:20241025T170000
DTSTAMP:20260728T014112
CREATED:20240611T071159Z
LAST-MODIFIED:20240611T071200Z
UID:7930-1729584000-1729875600@www.europabio.org
SUMMARY:World Orphan Drug Congress Europe 2024
DESCRIPTION:The World Orphan Drug Congress Europe is the largest and most established orphan drug & rare disease event worldwide. Meet over 2000 attendees\, hear from 250 leading speakers\, and connect with 130 exhibitors as we bring together experts from the start-to-finish of orphan drugs. From regulation and policy to global pricing and gene therapy\, the Congress has it covered. \n\n\n\nOur attendees include the most senior individuals across the industry\, including; R&D\, Gene Therapy and Rare diseases\, Precision/Personalised Medicine\, Genetic Disorders\, Patient Advocacy and Engagement\, Associations in ATMPs\, Investors\, Regulatory Affairs Professionals\, Governmental Bodies and many more … \n\n\n\nUse code “EUBIO20” to save an additional 20% off the Pharma/Biotech and Standard packages.
URL:https://www.europabio.org/event/world-orphan-drug-congress-europe-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/06/Event-Website-Banner-EBIO-WODC-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241008T100000
DTEND;TZID=Europe/Brussels:20241010T180000
DTSTAMP:20260728T014112
CREATED:20240828T135105Z
LAST-MODIFIED:20240828T135930Z
UID:8158-1728381600-1728583200@www.europabio.org
SUMMARY:CPHI Milan
DESCRIPTION:EuropaBio is pleased to partner with CPHI Milan 2024\, the biggest international pharmaceutical industry event for the thirty fifth anniversary edition. This year’s edition held from the 8th to the 10th of October in Fiera Milano\, Italy promises to a packed agenda with over 150 expert international speakers with over 100 content sessions. \n\n\n\nJoin our Director General Dr Claire Skentelbery this year where she will be speaking on the 9th of October to discuss how cultivated meat has the potential to revolutionise biologic manufacturing. Join her in Hall 3 – 3F97 at 16:15 on 09/10/2024 to find out more. \n\n\n\n \n\n\n\n\nFind Out More & Register Here
URL:https://www.europabio.org/event/cphi-milan/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/08/CPHI-x-EuropaBio-2024-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241002T170000
DTEND;TZID=Europe/Brussels:20241002T193000
DTSTAMP:20260728T014112
CREATED:20240827T080153Z
LAST-MODIFIED:20240827T080535Z
UID:8151-1727888400-1727897400@www.europabio.org
SUMMARY:Enhancing Europe's Pharma and Biotech Competitiveness and Open Strategic Autonomy
DESCRIPTION:Join our Director General Dr Claire Skentelbery on 2 October 2024 where she will be speaking at the Novartis & BritCham event “Enhancing Europe’s Pharma and Biotech Competitiveness and Open Strategic Autonomy”. \n\n\n\n\nFind Out More & Register Here
URL:https://www.europabio.org/event/enhancing-europes-pharma-and-biotech-competitiveness-and-open-strategic-autonomy/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/08/BritCham-Novartis-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240710T080000
DTEND;TZID=Europe/Brussels:20240711T170000
DTSTAMP:20260728T014112
CREATED:20240531T135225Z
LAST-MODIFIED:20240531T135227Z
UID:7893-1720598400-1720717200@www.europabio.org
SUMMARY:CURIOUS­ FUTURE INSIGHT™ CONFERENCE
DESCRIPTION:Over the millennia science & technology have steadily advanced\, but key unsolved challenges remain\, and much more is possible. The Curious – Future Insight™ Conference brings together some of the world’s brightest scientists and most accomplished innovators to present their work and explore the future of science and technology\, solving the challenges of today and enabling the dreams of a better tomorrow. \n\n\n\nThe Curious – Future Insight™ conference featurestop speakers and Nobel laureates from all over theworld\, among them: \n\n\n\n\nEmmanuelle Charpentier\, MPI (2018)\n\n\n\nSteven Chu\, Stanford University (2024)\n\n\n\nRobert Langer\, MIT (2024)\n\n\n\nSatya Nadella\, CEO Microsoft (2018)\n\n\n\nUğur Şahin\, CEO BioNTech (2024)\n\n\n\nRandy Schekman\, Berkeley (2024)\n\n\n\nThomas C. Südhof\, Stanford University (2024\, 2022)\n\n\n\nCraig Venter\, Craig Venter Institute (2018)
URL:https://www.europabio.org/event/curious-future-insight-conference/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Curious-Insights-Banner-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240416T083000
DTEND;TZID=Europe/Brussels:20240416T120000
DTSTAMP:20260728T014112
CREATED:20240326T082922Z
LAST-MODIFIED:20240326T083218Z
UID:7614-1713256200-1713268800@www.europabio.org
SUMMARY:RARE DISEASES FORUM 2024
DESCRIPTION:Against the backdrop of the Belgian EU Council Presidency\, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations\, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. \n\n\n\n \n\n\n\nAbout ‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences\, fostering investment in the rare diseases sector\, and examining the benefits of a competitive agenda for those with rare diseases.  \n\n\n\nThe event is convened by Global Counsel on behalf of the forum partners\, EURORDIS\, RaDiOrg\, EFPIA\, Eucope\, EuropaBio\, Pharma.be\, UCB\, Novo Nordisk\, Sanofi & Takeda.
URL:https://www.europabio.org/event/rare-diseases-forum-2024/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Event-Banner-Website-updated.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240307T130000
DTEND;TZID=Europe/Brussels:20240307T143000
DTSTAMP:20260728T014112
CREATED:20240209T095401Z
LAST-MODIFIED:20240306T151454Z
UID:7385-1709816400-1709821800@www.europabio.org
SUMMARY:EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
DESCRIPTION:Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies. \n\n\n\nFollowing the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem\, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe\, EU patients and economies within a global race towards health security and competitiveness. \n\n\n\nThe event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients. \n\n\n\nThe webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend\, please register below. \n\n\n\nAgenda: \n\n\n\n\nWelcome & Introduction: 13:00 – 13:05\, Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n\nReport Presentation and Q&A: 13:05 – 13:30\, Antun Sablek & Tim Wilsdon\, Charles River Associates\n\n\n\nPanel Discussion and Q&A: 13:30 – 14:25\, Panelists: John James Ricketts\, Noel Minnis\, Thomas Bols\, Tineke Van hooland\, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.\n\n\n\nConcluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n \n\n\n\nSpeakers: Moderated by Dr Claire Skentelbery\, EuropaBio \n\n\n\n\nAntun Sablek\, Charles River Associates\n\n\n\nJohn James Ricketts\, Eli Lilly\n\n\n\nNoel Minnis\, Takeda\n\n\n\nThomas Bols\, PTC Therapeutics\n\n\n\nTim Wilsdon\, Charles River Associates\n\n\n\nTineke Van hooland\, Bio.be\n\n\n\nWojciech Nowak\, Novartis\n\n\n\nYordan Aleksandrov\, Pfizer\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/europabio-webinar-how-will-the-revision-eu-general-pharmaceutical-legislation-impact-europes-innovation-ecosystem-and-biotechnology-companies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/CRA-Webinar-Banner-Event-Website.png
END:VEVENT
END:VCALENDAR